This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Johnson & Johnson gets antitrust claims in Remicade case sent to arbitration

( September 13, 2019, 13:36 GMT | Official Statement) -- MLex Summary: The US Court of Appeals for the Third Circuit has determined that Rochester Drug Cooperative’s antitrust claims against Johnson & Johnson fall under an arbitration agreement between the companies. RDC, on behalf of direct purchasers, accused J&J of unlawfully maintaining a monopoly over the drug Remicade through exclusionary contracts, resulting in higher prices. The panel remanded the case and referred it to arbitration.See document below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections